ImmunoGen, Inc. Announces Webcast of Presentation at the 7th Annual JMP Securities Research Conference
More News related to IMGN
- ImmunoGen (IMGN) Sells 7.8M Shares To Ziff Asset Management at $3.20/Sh
- ImmunoGen, Inc. Raises $25.0 Million in Registered Direct Offering of Common Stock
- Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes
- Unusual 11 Mid-Day Movers 6/3: GRO, LNG, COIN, OMNI Higher; NOOF, MIND, IMGN, CHU Lower
- ImmunoGen, Inc. Announces Presentation of Encouraging Clinical Findings with Trastuzumab-DM1 at ASCO
More News related to Press Releases
- Governor Rendell to Sign Budget
- Media Advisory/Natural Resources Canada: Minister Lunn Highlights Critical Importance of Natural Resources to Rural Communities
- TSX Venture Exchange Daily Bulletins for July 4, 2008
- Baja Mining Releases Video Presentation on Financing Completion
- Baja Mining Releases Video Presentation on Financing Completion
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen, Inc. (Nasdaq: IMGN) today announced that its presentation at the 7th Annual JMP Securities Research Conference will be webcast live. The presentation is scheduled to begin at 8:00 a.m. PDT on May 19, 2008, and will be given at The Ritz-Carlton, San Francisco, CA. The presentation will provide an update on ImmunoGen.
The webcast can be accessed through the "Investor Information" section of the ImmunoGen website, http://www.immunogen.com. Following the live webcast, a replay of the presentation will be available at the same location until May 26, 2008.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company's proprietary Tumor-Activated Prodrug (TAP) technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. Two TAP compounds wholly owned by ImmunoGen are in clinical testing - IMGN901 and IMGN242. Three TAP compounds are in clinical testing through ImmunoGen's collaborations with other companies - trastuzumab-DM1 (T-DM1), in development by Genentech, and AVE9633 and SAR3419, in development by sanofi-aventis. Additionally, the naked antibody compound, AVE1642, is in clinical testing through the Company's collaboration with sanofi-aventis. Multiple compounds are in research/preclinical development through ImmunoGen's collaborations and internal programs.
Source: ImmunoGen, Inc.
Related Categories
Press ReleasesStocks Mentioned
-0.08Sign up for StreetInsider Free!
Recieve full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
